000 | 01988 a2200517 4500 | ||
---|---|---|---|
005 | 20250515004531.0 | ||
264 | 0 | _c20060612 | |
008 | 200606s 0 0 eng d | ||
022 | _a1592-8721 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPrebet, Thomas | |
245 | 0 | 0 |
_aMobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib. _h[electronic resource] |
260 |
_bHaematologica _cNov 2005 |
||
300 |
_aECR36 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xtherapeutic use |
650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
650 | 0 | 4 | _aBenzamides |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 |
_aCytarabine _xtherapeutic use |
650 | 0 | 4 | _aDrug Resistance, Neoplasm |
650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xantagonists & inhibitors |
650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xpharmacology |
650 | 0 | 4 | _aHematopoietic Stem Cell Mobilization |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImatinib Mesylate |
650 | 0 | 4 |
_aInterferons _xtherapeutic use |
650 | 0 | 4 | _aLenograstim |
650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
650 | 0 | 4 |
_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aPeripheral Blood Stem Cell Transplantation |
650 | 0 | 4 |
_aPiperazines _xpharmacology |
650 | 0 | 4 |
_aPyrimidines _xpharmacology |
650 | 0 | 4 |
_aRecombinant Proteins _xpharmacology |
650 | 0 | 4 | _aRemission Induction |
650 | 0 | 4 | _aTransplantation, Autologous |
700 | 1 | _aTigaud, Isabelle | |
700 | 1 | _aHayette, Sandrine | |
700 | 1 | _aClapisson, Gilles | |
700 | 1 | _aPhilip, Irène | |
700 | 1 | _aMichallet, Mauricette | |
700 | 1 | _aNicolini, Franck E | |
773 | 0 |
_tHaematologica _gvol. 90 Suppl _gp. ECR36 |
|
999 |
_c15892415 _d15892415 |